Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IGM Biosciences, Inc.IGMS · Entity 76422 | Director | September 17, 2019 | September 17, 2019 |
| Neurogene Inc.AQXP · Entity 5160 | Director | March 23, 2017 | March 27, 2017 |
| Prelude Therapeutics IncPRLD · Entity 5561 | Director | September 24, 2020 | September 24, 2020 |
| Zymeworks BC Inc.ZYME · Entity 12038 | Director | May 06, 2021 | May 07, 2021 |
| Zymeworks Inc.ZYME · Entity 4458 | Director | January 12, 2026 | January 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IGM Biosciences, Inc.
Report date September 17, 2019 · Filed September 17, 2019
This filing explicitly reported no securities owned.
Neurogene Inc.
Report date March 23, 2017 · Filed March 27, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36 |
Reported balance
Holding disclosure · report date 2017-03-23 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 36 |
Prelude Therapeutics Inc
Report date September 24, 2020 · Filed September 24, 2020
This filing explicitly reported no securities owned.
Zymeworks BC Inc.
Report date May 06, 2021 · Filed May 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.49 · Expires 2031-05-05 | Direct | 9,000 |
Reported balance
After 2021-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-05-06 · Grant · Acquired 9,000 · Balance 9,000 F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on date of next annual general meeting following grant date of May 6, 2021.
Zymeworks Inc.
Report date January 12, 2026 · Filed January 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.16 · Expires 2036-01-11 | Direct | 11,500 |
Reported balance
After 2026-01-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-12 · Grant · Acquired 11,500 · Balance 11,500 F1: Stock options vest on January 12, 2027. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Expires 2027-01-12 | Direct | 7,700 |
Reported balance
After 2026-01-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-12 · Grant · Acquired 7,700 · Balance 7,700 F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3: RSUs vest on January 12, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Stock options vest on January 12, 2027.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.
F3: RSUs vest on January 12, 2027.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 12, 2026 Filed Jan 12, 2026 20:56 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantRestricted Stock Unit · Derivative | 7,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-010860 · ownership.xml · derivative · entry 2 Neu Kelvin · CIK 0001554699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,700 Underlying: Common Stock · 7,700 shares Expires 2027-01-12 F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock. F3 · derivative.exercise_date: RSUs vest on January 12, 2027. F3 · derivative.expiration_date: RSUs vest on January 12, 2027. Read SEC document |
| January 12, 2026 Filed Jan 12, 2026 20:56 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 11,500 | $0.00 Strike: $23.16 | $0.00 |
DisclosureSEC source: 0001193125-26-010860 · ownership.xml · derivative · entry 1 Neu Kelvin · CIK 0001554699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 11,500 shares Expires 2036-01-11 F1 · derivative.exercise_date: Stock options vest on January 12, 2027. Read SEC document |
| December 10, 2024 Filed Dec 12, 2024 17:56 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 31,000 | $0.00 Strike: $13.06 | $0.00 |
DisclosureSEC source: 0000950170-24-135928 · ownership.xml · derivative · entry 1 Neu Kelvin · CIK 0001554699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,000 Underlying: Common Stock · 31,000 shares Expires 2034-12-09 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 10, 2024. Read SEC document |
| December 07, 2023 Filed Dec 8, 2023 17:26 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 37,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0000950170-23-069116 · ownership.xml · derivative · entry 1 Neu Kelvin · CIK 0001554699 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2033-12-06 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 7, 2023. Read SEC document |
| December 21, 2022 Filed Dec 23, 2022 19:00 UTC | Zymeworks Inc. ZYME · Entity 4458 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $8.75 | $0.00 |
DisclosureSEC source: 0000899243-22-039323 · doc4.xml · derivative · entry 1 Neu Kelvin · CIK 0001554699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-12-20 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of December 21, 2022. Read SEC document |
| May 06, 2021 Filed May 7, 2021 20:45 UTC | Zymeworks BC Inc. ZYME · Entity 12038 | GrantStock Option (Right to Buy) · Derivative | 9,000 | $0.00 Strike: $29.49 | $0.00 |
DisclosureSEC source: 0000899243-21-018768 · doc4.xml · derivative · entry 1 Neu Kelvin · CIK 0001554699 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires 2031-05-05 F1 · derivative.exercise_date: Stock options vest on date of next annual general meeting following grant date of May 6, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.